Showing results (31-40 of 92) with videos related to

Sort By:
Pageof 10
Journal of Neurology|October 5, 2018
Vitamin D for the treatment of multiple sclerosis: a meta-analysisLaurie McLaughlin, Laura Clarke, Elham Khalilidehkordi, et al.
Brain : a Journal of Neurology|May 29, 2000
Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK surveyS A Broadley, J Deans, S J Sawcer, et al.
Clinical and Experimental Immunology|June 3, 2021
Magnetic resonance imaging in neuromyelitis optica spectrum disorderLaura Clarke, Simon Arnett, Kate Lilley, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|January 27, 2020
PRES-like presentation in MOG antibody-related demyelination (MARD)Joel Corbett, Sandeep Bhuta, Kerri Prain, et al.
Human Molecular Genetics|January 13, 2006
Proteolytic cleavage of polyglutamine-expanded ataxin-3 is critical for aggregation and sequestration of non-expanded ataxin-3Annette Haacke, Sarah A Broadley, Raina Boteva, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 25, 2000
Multiple sclerosis and tonsillectomy: no evidence for an influence on the development of disease or clinical phenotypeS A Broadley, J Deans, S J Chataway, et al.
Journal of Cannabis Research|April 21, 2025
Effect of cannabinoids on glutamate levels in the human brain: a systematic review and meta-analysisBerzenn Urbi, Vincent Sapaen, Ian Hughes, et al.
Journal of Neurology|June 11, 2024
Long-term outcomes of ADEM-like and tumefactive presentations of CNS demyelination: a case-comparison analysisSimon V Arnett, Kerri Prain, Sudarshini Ramanathan, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|June 13, 2013
Autoimmune thyroid disease in the use of alemtuzumab for multiple sclerosis: a reviewAlgenes Alphius Aranha, Saima Amer, Elham Saleh Reda, et al.
Multiple Sclerosis and Related Disorders|January 30, 2022
Low vitamin D levels do not predict risk of autoimmune disease following alemtuzumab treatment for multiple sclerosisSimon Arnett, Sofia Jimenez Sanchez, Jennifer Downing, et al.
Pageof 10